A peptide targeted fluorescence probe for precision surgery of head and neck cancer
Award amount
$294,505Program and phase
SBIR · Phase IAward year
2024Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- MOLECULAR THERANOSTICS, LLC
- Proposal award date
- 2024-07-17
- Contract end date
- 2025-07-16
- UEI
- L1VLYM9HZNK3
- Solicitation number
- PA23-230
- Topic code
- NIDCR
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Development of peptide drug conjugates for cancer therapy
- Commercialization of an MRI contrast agent for differential diagnosis of prostate cancer
- Commercialization of an MRI contrast agent for differential diagnosis ofprostate cancer.
- Commercialization of targeted MRI contrast agents for prostate cancer imaging.
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- RegendoGEL for guided pulp and dentin regeneration
- CraniaMap: Joint Solution for Auto-Segmentation and Landmarking from CBCT Scans
- Improving Caries Diagnosis with Targeted Nanoparticle-Enhanced AI-Assisted Intraoral Imaging
- Epigenetic Compounds Stimulating Dental Bone Repair
- AI-linked cytomics-on-a-chip to enable near-real time identification and management of oral lichenoid lesions in primary care
Research funding history
5 SBIR/STTR records share this UEI (2015–2024). Reported award amounts total $4,892,605. Reported amounts are not federal obligations.
Phases: Phase I, Phase II – Direct to Phase II, Phase II
Agencies: Department of Health and Human Services